MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 341463 | Name: XR 808

Description:

WARNING: This product is for research use only, not for human or veterinary use.

XR 808 is a biochemical.

Chemical Structure

XR 808
XR 808
CAS#167826-88-2

Theoretical Analysis

MedKoo Cat#: 341463

Name: XR 808

CAS#: 167826-88-2

Chemical Formula: C17H34N2O3

Exact Mass: 314.2569

Molecular Weight: 314.47

Elemental Analysis: C, 64.93; H, 10.90; N, 8.91; O, 15.26

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
XR-808; XR 808; XR808; .
IUPAC/Chemical Name
(4R-(4alpha,5alpha,6beta,7beta))-Hexahydro-5,6-dihydroxy-4,7-bis(2-ethylbutyl)-2H-1,3-diazepin-2-one
InChi Key
KNEDFLBGINWTSV-WCVJEAGWSA-N
InChi Code
InChI=1S/C17H34N2O3/c1-5-11(6-2)9-13-15(20)16(21)14(19-17(22)18-13)10-12(7-3)8-4/h11-16,20-21H,5-10H2,1-4H3,(H2,18,19,22)/t13-,14-,15+,16+/m1/s1
SMILES Code
O=C1N[C@H](CC(CC)CC)[C@H](O)[C@@H](O)[C@@H](CC(CC)CC)N1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 314.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Zhang Y, Lei BH, Zou Q, Zhu QY, Lu ZJ, Wang Y. [Clinical efficacy of integrated traditional Chinese and Western medicine for castration-resistant prostate cancer]. Zhonghua Nan Ke Xue. 2017 Oct;23(10):922-927. Chinese. PubMed PMID: 29727544. 2: Chauchat L, Tanguay C, Caron NJ, Gagné S, Labrèche F, Bussières JF. Surface contamination with ten antineoplastic drugs in 83 Canadian centers. J Oncol Pharm Pract. 2018 Jan 1:1078155218773862. doi: 10.1177/1078155218773862. [Epub ahead of print] PubMed PMID: 29726786. 3: Pandey G, Mittapelly N, Banala VT, Mishra PR. Multifunctional Glycoconjugate Assisted Nanocrystalline Drug Delivery for Tumor Targeting and Permeabilization of Lysosomal-Mitochondrial Membrane. ACS Appl Mater Interfaces. 2018 May 4. doi: 10.1021/acsami.7b18699. [Epub ahead of print] PubMed PMID: 29726253. 4: Škereňová M, Mikulová V, Čapoun O, Švec D, Kološtová K, Soukup V, Honová H, Hanuš T, Zima T. Gene Expression Analysis of Immunomagnetically Enriched Circulating Tumor Cell Fraction in Castration-Resistant Prostate Cancer. Mol Diagn Ther. 2018 May 3. doi: 10.1007/s40291-018-0333-0. [Epub ahead of print] PubMed PMID: 29725990. 5: Schmidkonz C, Cordes M, Schmidt D, Bäuerle T, Goetz TI, Beck M, Prante O, Cavallaro A, Uder M, Wullich B, Goebell P, Kuwert T, Ritt P. (68)Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer. Eur J Nucl Med Mol Imaging. 2018 May 3. doi: 10.1007/s00259-018-4042-z. [Epub ahead of print] PubMed PMID: 29725716. 6: Hiroshige T, Eguchi Y, Yoshizumi O, Chikui K, Kumagai H, Kawaguchi Y, Onishi R, Hayashi T, Watanabe K, Mitani T, Saito K, Igawa T. Baseline prostate-specific antigen levels following treatment with abiraterone acetate as a prognostic factor in castration-resistant prostate cancer. Oncol Lett. 2018 May;15(5):6806-6814. doi: 10.3892/ol.2018.8263. Epub 2018 Mar 14. PubMed PMID: 29725416; PubMed Central PMCID: PMC5920147. 7: Tang M, Horsley P, Lewis CR. Emergency department presentations in early stage breast cancer patients receiving adjuvant and neoadjuvant chemotherapy. Intern Med J. 2018 May;48(5):583-587. doi: 10.1111/imj.13785. PubMed PMID: 29722200. 8: Marin S, Querol R, Campins L, Miarons M, Font A, Lianes P. Long-term abiraterone withdrawal syndrome. J Clin Pharm Ther. 2018 May 2. doi: 10.1111/jcpt.12693. [Epub ahead of print] PubMed PMID: 29722038. 9: Smit EF, Garon EB, Reck M, Cappuzzo F, Bidoli P, Cohen RB, Gao L, O'Brien LM, Lee P, Zimmermann A, Ferry DR, Melemed AS, Pérol M. Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer. Cancer Chemother Pharmacol. 2018 May 2. doi: 10.1007/s00280-018-3560-5. [Epub ahead of print] PubMed PMID: 29721850. 10: Basade M, Singhal M, Rathi AK, Nandi M, Minhas S, Goswami C, Shinde S, Parikh PM, Aggarwal S. Practical consensus recommendations regarding the management of HER2 neu positive metastatic breast cancer. South Asian J Cancer. 2018 Apr-Jun;7(2):146-150. doi: 10.4103/sajc.sajc_123_18. PubMed PMID: 29721483; PubMed Central PMCID: PMC5909294. 11: Shimanuki M, Imanishi Y, Sato Y, Nakahara N, Totsuka D, Sato E, Iguchi S, Sato Y, Soma K, Araki Y, Shigetomi S, Yoshida S, Uno K, Ogawa Y, Tominaga T, Ikari Y, Nagayama J, Endo A, Miura K, Tomioka T, Ozawa H, Ogawa K. Pretreatment monocyte counts and neutrophil counts predict the risk for febrile neutropenia in patients undergoing TPF chemotherapy for head and neck squamous cell carcinoma. Oncotarget. 2018 Apr 10;9(27):18970-18984. doi: 10.18632/oncotarget.24863. eCollection 2018 Apr 10. PubMed PMID: 29721176; PubMed Central PMCID: PMC5922370. 12: Chen BT, Sethi SK, Jin T, Patel SK, Ye N, Sun CL, Rockne RC, Haacke EM, Root JC, Saykin AJ, Ahles TA, Holodny AI, Prakash N, Mortimer J, Waisman J, Yuan Y, Somlo G, Li D, Yang R, Tan H, Katheria V, Morrison R, Hurria A. Assessing brain volume changes in older women with breast cancer receiving adjuvant chemotherapy: a brain magnetic resonance imaging pilot study. Breast Cancer Res. 2018 May 2;20(1):38. doi: 10.1186/s13058-018-0965-3. PubMed PMID: 29720224. 13: Sæther NH, Skuja E, Irmejs A, Maksimenko J, Miklasevics E, Purkalne G, Gardovskis J. Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer: a retrospective cohort analysis and literature review. Hered Cancer Clin Pract. 2018 Apr 27;16:9. doi: 10.1186/s13053-018-0092-2. eCollection 2018. PubMed PMID: 29719582; PubMed Central PMCID: PMC5924493. 14: Su CY, Chen M, Chen LC, Ho YS, Ho HO, Lin SY, Chuang KH, Sheu MT. Bispecific antibodies (anti-mPEG/anti-HER2) for active tumor targeting of docetaxel (DTX)-loaded mPEGylated nanocarriers to enhance the chemotherapeutic efficacy of HER2-overexpressing tumors. Drug Deliv. 2018 Nov;25(1):1066-1079. doi: 10.1080/10717544.2018.1466936. PubMed PMID: 29718725. 15: Uemura K, Miyoshi Y, Kawahara T, Ryosuke J, Yamashita D, Yoneyama S, Yokomizo Y, Kobayashi K, Kishida T, Yao M, Uemura H. Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel. BMC Cancer. 2018 May 2;18(1):501. doi: 10.1186/s12885-018-4401-y. PubMed PMID: 29716525. 16: Lin JZ, Zhu JG, Wu HF, Li JM, DE W, Wang ZJ. [Expression of AXL enhances docetaxel-resistance of prostate cancer cells]. Zhonghua Nan Ke Xue. 2017 Apr;23(4):302-308. Chinese. PubMed PMID: 29714413. 17: Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, Hatton MQ, Hoadley KA, Parikh J, Parker P, Perou CM, Roylance R, Shah V, Shaw A, Smith IE, Timms KM, Wardley AM, Wilson G, Gillett C, Lanchbury JS, Ashworth A, Rahman N, Harries M, Ellis P, Pinder SE, Bliss JM. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med. 2018 Apr 30. doi: 10.1038/s41591-018-0009-7. [Epub ahead of print] PubMed PMID: 29713086. 18: Sonpavde G, Pond GR, Rosenberg JE, Choueiri TK, Bellmunt J, Regazzi AM, Mullane SA, Necchi A, Raggi D, Lee JL, Lee S, Simpson J, Derleth CL, Lin SW, Bajorin DF. Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy. Clin Genitourin Cancer. 2018 Apr 6. pii: S1558-7673(18)30089-2. doi: 10.1016/j.clgc.2018.03.016. [Epub ahead of print] PubMed PMID: 29706503. 19: Iocca O, Farcomeni A, Di Rocco A, Di Maio P, Golusinski P, Pardiñas López S, Savo A, Pellini R, Spriano G. Locally advanced squamous cell carcinoma of the head and neck: A systematic review and Bayesian network meta-analysis of the currently available treatment options. Oral Oncol. 2018 May;80:40-51. doi: 10.1016/j.oraloncology.2018.03.001. Epub 2018 Mar 27. PubMed PMID: 29706187. 20: Seidlitz T, Merker SR, Rothe A, Zakrzewski F, von Neubeck C, Grützmann K, Sommer U, Schweitzer C, Schölch S, Uhlemann H, Gaebler AM, Werner K, Krause M, Baretton GB, Welsch T, Koo BK, Aust DE, Klink B, Weitz J, Stange DE. Human gastric cancer modelling using organoids. Gut. 2018 Apr 27. pii: gutjnl-2017-314549. doi: 10.1136/gutjnl-2017-314549. [Epub ahead of print] PubMed PMID: 29703791.

View History

WZ4002-hydroxy

WZ4002-hydroxy

IC-2

IC-2

Myrcenyl acetate

Myrcenyl acetate

F-1673

F-1673

C.I. 48020

C.I. 48020

S-acetyl-PEG4-Thiol

S-acetyl-PEG4-Thiol